Clinical trials: Left Atrial Appendage Occluder
Atrial Fibrillation, Stroke
Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder
This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).
- Trial name
- NCT01920412
- Testing
- LAmbre Left Atrial Appendage(LAA) Occluder
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Ischemic Stroke, Atrial Fibrillation
Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
The project is a multicenter, open-label, randomized medical experiment, which was designed to evaluate the efficacy and safety of single-stage pulmonary vein isolation (PVI) and implantation of left atrial appendage occluder…
- Trial name
- PILOS-AF (NCT06212674)
- Testing
- PVI + LAAO, single stage, LAAO, NOAC
- Where
- 2 sites in Poland
- Volunteers
- 240 people
- Sponsor
- Medical University of Silesia
Non Valvular Atrial Fibrillation
LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System for Patients With Non-Valvular Atrial Fibrillation
Worldwide, atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. The prevalence of AF gradually increases with age; its prevalence is 0.5% ~ 0.8% among 45 ~ 59 year-olds, 1.8% ~ 5.9% among 60 ~ 69 year-olds…
- Trial name
- LAmbre2 (NCT07455539)
- Testing
- LAmbre II Left Atrial Appendage Occluder
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Non-Valvular Atrial Fibrillation
Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
The purpose of the study is to assess the safety and performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in LAA (Left Atrial Appendage) closure for patients with non-valvular atrial…
- Trial name
- Omega (NCT04829929)
- Testing
- Omega™LAA Occluder implantation
- Where
- 13 sites in Denmark, Germany and 4 more
- Volunteers
- 200 people
- Sponsor
- Eclipse Medical Ltd.
Atrial Fibrillation, Cardiac Perforation
Complications From Left Atrial Appendage Occluder
The following case reported a rare complication of left atrial appendage perforation complicated by cardiac tamponade during LAAO device deployment and its corresponding surgical management
- Conditions
- Atrial Fibrillation, Cardiac Perforation, Cardiac Tamponade
- Trial name
- NCT05086653
- Testing
- Surgery
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Kaohsiung Medical University
Non-valvular Atrial Fibrillation (NVAF), High Risk of Stroke
A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke
This study aims to evaluate the endotheliation efficacy of the AnchorMane® Left Atrial Appendage Occluder in non-valvular atrial fibrillation patients at high stroke risk.
- Trial name
- AnchorMan-NVAF (NCT07396493)
- Testing
- Intra-operative application of LAAC
- Volunteers
- 306 people
- Sponsor
- Shanghai Zhongshan Hospital
Atrial Fibrillation
Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation
This is a prospective, non-randomized, study of the safety and efficacy of the Occlutech® LAA occluder indicated for percutaneous LAA closure in adult male or female patients with atrial fibrillation.
- Trial name
- OLAAC (NCT02105584)
- Testing
- Implantation of LAA closure device
- Where
- 7 sites in Germany, United Kingdom
- Volunteers
- 78 people
- Sponsor
- Occlutech International AB
Atrial Fibrillation, Stroke
Amulet™ ADVANCE LAA
This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. Over 600 subjects have been enrolled at 16 US clinical sites.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- NCT05997446
- Testing
- Left atrial appendage occlusion (LAAO)
- Where
- 16 sites in United States
- Volunteers
- 610 people
- Sponsor
- Abbott Medical Devices